Product Description
BIIB063 is a high affinity MAb, engineered to reduce Fc effector function and avoid half antibody formationin vivo(IgG4P).
Mechanisms of Action: CD40 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 234HV101 | P1 |
Terminated |
Healthy Volunteers |
2016-06-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|